Dismantling the pathophysiology of asthma using imaging
Asthma remains an important disease worldwide, causing high burden to patients and healthcare systems and presenting a need for better management and ultimately prevention and cure. Asthma is a very heterogeneous condition, with many different pathophysiological processes. Better measurement of those pathophysiological processes are needed to better phenotype disease, and to go beyond the current, highly limited measurements that are currently used: spirometry and symptoms. Sophisticated three-dimensional lung imaging using computed tomography and ventilation imaging (single photon emission computed tomography and positron emission tomography) and magnetic resonance imaging and methods of lung imaging applicable to asthma research are now highly developed. The body of current evidence suggests that abnormalities in structure and ventilatory function measured by imaging are clinically relevant, given their associations with disease severity, exacerbation risk and airflow obstruction. Therefore, lung imaging is ready for more widespread use in clinical trials and to become part of routine clinical assessment of asthma.
This article explores the most relevant issues facing the role of e-Health and its sub-category—mobile health (mHealth)—in promoting treatment adherence in childhood asthma, focusing on current evidence gaps and limitations, and future research perspectives.
ConclusionsPrognosis in patients with CRSwNP was inferior to that in patients with CRSsNP. Asthma was the only factor that increased the chance of recurrence in patients with either CRSsNP or CRSwNP.
This study supports a positive benefit-risk profile for long-term mepolizumab treatment in these patients.
Publication date: Available online 14 August 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Maxime Cormier, Simone Chaboillez, Catherine Lemière
This article was originally published on Undark. Read the original article.
Neutrophilic inflammation in asthma is associated with interleukin (IL)-17A, corticosteroid-insensitivity and bronchodilator-induced forced expiratory volume in 1 s (FEV1) reversibility. IL-17A synergises with tumour necrosis factor (TNF)-α in the production of the neutrophil chemokine CXCL-8 by primary bronchial epithelial cells (PBECs). We hypothesised that local neutrophilic inflammation in asthma correlates with IL-17A and TNF-α-induced CXCL-8 production by PBECs from asthma patients. PBECs from most asthma patients displayed an exaggerated CXCL-8 production in response to TNF-α and IL-17A, but n...
Asthma is a chronic disease that seriously harms the health of patients. Oxidative stress is involved in asthma. As an oxidative stress-inducible protein, sestrin2 is elevated in oxidative stress-related disea...
Severe Combined Immune Deficiency (SCID) is the first primary immunodeficiency amenable to population based newborn screening (NBS) and is now available in all 50 states and Puerto Rico. NBS for SCID uses real time qPCR to measure the number of copies of T cell restriction excision circles (TREC) in DNA from newborn dried blood spots (DBS) and reliably detects severe T cell lymphopenia (TCL) at birth. SCID is the primary condition detected using this assay. However, it is well known that many secondary conditions, having varying degrees of TCL, are identified through SCID NBS.